Skip to content

Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients

Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients: A Double-Blinded Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06890221
Acronym
IPENIPA
Enrollment
114
Registered
2025-03-21
Start date
2025-03-07
Completion date
2026-12-31
Last updated
2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3), Mastectomy Patient

Keywords

bioimpedance phase angle, nutritional intervention, oral nutritional supplement

Brief summary

The goal of this clinical trial is to measure the mean difference of phase angle after nutritional intervention in breast cancer patients. The main question it aims to answer is: 1\. Can perioperative nutrition interventions improve phase angle in relation to other bioimpedance parameters, handgrip strength and surgical outcomes in breast cancer population? Researchers will compare oral nutritional supplement to a placebo to see if oral nutritional supplement can improve phase angle. Participants will: 1. Be randomized into either arm 2. Take oral nutritional supplement or placebo according to the result of randomization for 7 days preoperatively and 30 days postoperatively 3. Have their measurements (weight, height, phase angle, handgrip strength) done at least 7 days preoperative, 1 day preoperative and 30 days postoperative

Interventions

DIETARY_SUPPLEMENTB-Crobes intake complete nutrition

Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.

DIETARY_SUPPLEMENTPlacebo

Contains full cream dairy milk

Sponsors

B-Crobes Laboratory (M) Sdn Bhd
CollaboratorUNKNOWN
University of Malaya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Double blinded

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female * Histopathologically confirmed operable breast cancer * Aged 18 of years and above * Consented and scheduled for mastectomy

Exclusion criteria

* On enteral supplementation prior to the study * Lactose intolerance * Pregnant or lactating * Previous history of gastrectomy or small bowel resection surgery * Advanced breast cancer staging, presence of pacemaker, decompensated liver disease, end stage renal failure, uncontrolled diabetes, on steroid therapy or complementary traditional medications

Design outcomes

Primary

MeasureTime frameDescription
Mean difference of phase angle after nutritional interventionFrom enrollment to 30 days post operationTo measure the mean difference of phase angle between groups after nutritional intervention

Secondary

MeasureTime frameDescription
Changes in handgrip strengthFrom enrollment to 30 days post operationTo study the changes on handgrip strength, body composition by bioimpedance analysis (skeletal muscle mass, skeletal muscle mass index, fat free mass and fat mass) after nutritional interventions.
Correlation of phase angle with bioimpedance analysis parametersFrom enrollment to 30 days post operationTo describe the correlation of phase angle with nutritional status, handgrip strength, and body compositions by bioimpedance analysis (Skeletal muscle mass, skeletal muscle mass index, fat free mass, and fat mass).
Potential factors associated with postoperative complicationsFrom enrollment to 30 days post operationTo identify the potential factors associated with complications and readmission in 30-days post-mastectomy participants.
Cutoff value of phase angleFrom enrollment to 30 days post operationTo identify the cutoff value of PA in relation to GLIM malnutrition, nutrition risk, and sarcopenia

Countries

Malaysia

Contacts

Primary ContactWai Yin Soo, MD
waiyin@ummc.edu.my+60 16-365 8711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026